

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 October 2005 (20.10.2005)

PCT

(10) International Publication Number
WO 2005/097194 A1

(51) International Patent Classification⁷: A61K 47/00,
A61P 9/10

Hong-Gi [KR/KR]; Samik 2-cha Apt. 202-604, Homae-sil-dong, Kwonsun-gu, Suwon-si, Kyungki-do 441-708 (KR). CHI, Moon-Hyuk [KR/KR]; 201-ho, #290-60, Gosaik-dong, Kwonsun-gu, Suwon-si, Kyungki-do 441-360 (KR). RYU, Jae-Kuk [KR/KR]; Taesan 1-cha Apt. 102-1506, Gosaik-dong, Kwonsun-gu, Suwon-si, Kyungki-do 441-360 (KR). JUNG, Si-Young [KR/KR]; 302-ho, #290-4, Gosaik-dong, Kwonsun-gu, Suwon-si, Kyungki-do 441-360 (KR). KIM, Yong-II [KR/KR]; 202-ho, #913-5, Guun-dong, Kwonsun-gu, Suwon-si, Kyungki-do 441-340 (KR).

(21) International Application Number: PCT/KR2005/001021

(22) International Filing Date: 8 April 2005 (08.04.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10-2004-0024734 10 April 2004 (10.04.2004) KR

(74) Agents: JANG, Seongku et al.; 19th Fl., KEC Building, #275-7, Yangjae-dong, Seocho-ku, Seoul 137-130 (KR).

(71) Applicant (for all designated States except US): HANMI PHARM. CO., LTD. [KR/KR]; #893-5, Hajeo-ri, Paltan-myeon, Hwaseong-gun, Kyungki-do 445-910 (KR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,


(72) Inventors; and

(75) Inventors/Applicants (for US only): WOO, Jong-Soo [KR/KR]; Daewol Maeul 821-105, #914, Jeongja-dong, Jangan-gu, Suwon-si, Kyungki-do 440-300 (KR). YI,

[Continued on next page]

(54) Title: SUSTAINED RELEASE FORMULATION FOR ORAL ADMINISTRATION OF HMG-COA REDUCTASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF

—○— Example 4 50 rpm —■— Example 4 100 rpm
—▲— Example 4 150 rpm



WO 2005/097194 A1

(57) Abstract: The sustained release formulation for oral administration of an HMG-CoA reductase inhibitor of the present invention can be easily and economically prepared and is capable of maintaining a constant drug level in blood by slowly releasing the HMG-CoA reductase inhibitor at a uniform rate for 24 hrs. Accordingly, the sustained release formulation of the present invention can be effectively used for lowering blood cholesterol and triglyceride levels.



TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.